Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-30
2007-01-30
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253050, C514S254090, C514S218000, C544S121000, C544S363000, C544S373000, C540S575000
Reexamination Certificate
active
10466250
ABSTRACT:
The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction
REFERENCES:
patent: 6294534 (2001-09-01), Nargund et al.
patent: WO 94 13696 (1994-06-01), None
patent: WO 99 55679 (1999-11-01), None
patent: WO 99 64002 (1999-12-01), None
patent: WO 00 74679 (2000-12-01), None
patent: WO 01 70337 (2001-09-01), None
patent: WO 01 70708 (2001-09-01), None
patent: WO 02 15909 (2002-02-01), None
patent: WO 02 059107 (2002-08-01), None
patent: WO 02 059108 (2002-08-01), None
patent: WO 02 059117 (2002-08-01), None
patent: WO 02 070511 (2002-09-01), None
Sebhat et al. Annual Reports in Medicinal Chemistry, vol. 38, p. 31-40 (2003).
Campfield et al. Science, vol. 280, p. 1383-1387 (1998).
Backer Ryan Thomas
Briner Karin
Collado Caño Ivan
De Frutos Garcia Oscar
Doecke Christopher William
Bernhardt Emily
Eli Lilly and Company
Jang Soonhee
Myers James B.
LandOfFree
Melanocortin receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Melanocortin receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanocortin receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3758504